Genomic Press: Bridging Neuroscience from Bench to Society
Welcome to Genomic Press, a paradigm shift in scientific publishing. Our initial focus encompasses psychiatry, neurology, and fundamental neuroscience. As we launch, our mission is clear: to forge a comprehensive bridge from molecular biology and genetics through clinical research, novel treatments, and trials, extending to societal impacts, including epidemiology and population science.
At Genomic Press, we recognize the continuum of scientific discovery and its potential to revolutionize our understanding of the brain and mind. We aim to cultivate a broad perspective of neuroscience, connecting the intricate components from genes and molecules to the complexities of mental health, neurological disorders, and their societal implications.
We are committed to fostering an environment that nurtures breakthroughs, champions innovation, and encourages discourse across the diverse spectrum of neuroscience. To this end, we are introducing new journals that provide researchers worldwide with platforms to showcase their insights and discoveries.
Our editorial process ensures swift, fair, and thorough peer review of all submissions. Experienced senior editors guide the evaluation of each manuscript based on its intellectual merit, regardless of the authors' affiliations or geographic location. Our editorial team works closely with authors, providing clear and constructive feedback to enhance the quality and impact of their research.
Recognizing the importance of research visibility in today's interconnected world, Genomic Press aims to maximize the exposure of authors' work. We utilize social media channels and press releases to spotlight research, ensuring it reaches a global audience and contributes to scientific discourse at the broadest level.
Genomic Press is not just a publishing house; we are your partners in scientific communication. As we prepare for our full-scale launch, we look forward to embarking on this exciting journey together, pushing the frontiers of neuroscience and contributing to improving global health. Join us as we work to transform the landscape of scientific publishing.
.
Publisher
Julio Licinio, MD, PhD, MBA, MS, FRANZCP, FAAHMS is the Publisher & CEO of Genomic Press. Dr. Licinio is also the Inaugural Editor-in-Chief (EIC) of our three journals, Genomic Psychiatry, Brain Medicine, and Psychedelics. In addition to his consecutive leadership of a center, a department, two institutes, and a medical school, he has maintained active programs of translational research on several fronts.
Dr. Licinio has over 30 years of experience as Editor-in-Chief, having founded and led four journals from inception to full indexing and hight impact. In the last seven years, Dr. Licinio has edited and published 44 articles by 9 Nobel Prize laureates, including 19 articles by the late Paul Greengard. Dr. Licinio raised the impact factor and rankings of the first journal he launched from non-existence to number 1 worldwide in 13 years.
Editorial Board
We have curated the Editorial Boards from among eminent international experts. Our Boards epitomize diversity in expertise, geographical representation, gender, and ethnicity. Please go the websites for Genomic Psychiatry, Brain Medicine, and Psychedelics for a detailed listing of each journal’s editorial board members and their affiliations.
PUBLIC INFORMATION OFFICER
Ma-Li Wong, MD, PhD, is the Public Information Officer (PIO) of Genomic Press, with primary responsibilities in public/media relations. Dr. Wong has had over 300 publications. Her research has been continuously federally funded for 25 years in the USA and Australia. She has been a tenured Professor since 1999 and among other honors she has attained the position of State University of New York Distinguished Professor. She also has over 20 years of experience as Associate Editor, Senior Editor, or Managing Editor of three highly successful journals. While a Professor at UCLA, she conducted a federally-funded community engagement outreach research program. She will leverage her substantial academic experience in three continents to manage our global media strategy.
Unraveling Complexity from DNA to Brain Disorders
Genomic Press will redefine the narrative of medical research and its impact on society. Our focus extends from the intricacies of our genetic blueprints to the final manifestations of complex disorders. While every life story begins with the DNA, we are far more than just our genes. The final health outcomes in common and complex disorders represent the confluence of a myriad of processes. This includes not only genetic and biochemical factors but also metabolic and inflammatory responses. These biological phenomena occur in the backdrop of our interactions with a vast range of environmental exposures, from chemical agents to social influences. Our objective is to foster a broad understanding of these complex interactions. We aim to publish research along the continuum from genetic underpinnings all the way to the biological and environmental contexts that ultimately influence health and disease.
New Journals Now Accepting Submissions
We are excited to announce that Genomic Press, a pioneering force in scientific publishing, has launched three groundbreaking scholarly journals!
In our mission to shape the future of genomics and related fields, we have introduced the following publications:
Brain Medicine: From Neurons to Behavior and Better Health. We cover innovation in fundamental neuroscience, translational initiatives, and causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface. To submit a paper, go to the Brain Medicine submission website.
Genomic Psychiatry: Advancing Science from Genes to Society. This broad journal publishes cutting-edge research across the continuum from genes and molecules to society and public health. To submit a paper, go to the Genomic Psychiatry submission website.
Psychedelics: The Journal of Psychedelic Pharmacology. This is the first medical and scientific journal exclusively dedicated as a state-of-the-art resource for the latest discoveries and advancements in the realm of psychedelic substances and their potential therapeutic uses. To submit a paper, go to the Psychedelics submission website.
These journals represent our commitment to facilitating discourse and collaboration within this exciting and highly promising scientific arena. We invite researchers worldwide to submit their high-quality research papers through the provided submission URLs.
Our Open Access model ensures that vital insights are made widely available, breaking down barriers in knowledge exchange and maximizing the impact of your work.
For more detailed information about each journal, including submission guidelines and editorial policies, please visit the respective journal's webpage through the links provided earlier.
At Genomic Press, we are excited to offer these new platforms for scientific dialogue and discovery. Join us in this exciting journey as we chart new territories in genomic psychiatry and psychedelic pharmacology.
Welcome to the future of scientific publishing!
